<DOC>
	<DOCNO>NCT01529645</DOCNO>
	<brief_summary>This study evaluate safety efficacy 9 different vaccine contain aP ( acellular pertussis ) TdaP ( acellular pertussis , tetanus diphtheria ) healthy subject 18 40 year age .</brief_summary>
	<brief_title>Safety Dose Ranging Study Acellular Pertussis Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines Healthy Adults Ages 18 40 Years</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Healthy male female individual 18 40 year age ( inclusive ) provide informed consent . 2 . Individuals able contact duration study . 1 . Individuals receive vaccine contain T , D , pertussis ( aP whole cell ) , diagnose pertussis disease , household exposure pertussis within past 8 year . 2 . If female , `` childbearing potential '' , sexually active , use `` acceptable contraceptive method '' least 2 month prior study entry : 1 . Of childbearing potential defined status post onset menarche meeting follow condition : menopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy , status hysterectomy . 2 . Acceptable birth control method define one following : Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) ; Barrier ( condom spermicide diaphragm spermicide ) every time intercourse ; Intrauterine device ( IUD ) ; Monogamous relationship vasectomize partner . Partner must vasectomize least six month prior subject 's study entry . 3 . If female childbearing potential sexually active , refusal use `` acceptable contraceptive method '' 3 week last study vaccination . 4 . Any positive indeterminate pregnancy test . 5 . Female individual pregnant breastfeeding . 6 . Individuals contraindication , warning and/or precaution vaccination Boostrix Tdpur specify within summary product characteristic . 7 . Individuals clinically significant active infection ( assessed investigator ) oral body temperature ≥38°C/100.4ºF within 3 day intend date vaccination . 8 . Known hypersensitivity allergy diphtheria , tetanus , pertussis vaccine ( include excipients investigational study vaccine , control placebo summarize protocol section 5.0 ) . 9 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , might interfere subject 's ability participate study . 10 . Individuals progressive severe neurologic disorder , seizure disorder GuillianBarré syndrome . 11 . Individuals history illness , opinion investigator , might interfere result study pose additional risk individual due participation study . 12 . Known suspected impairment/alteration immune function , include : 1 . Chronic use oral steroid ( ≥15 day use ) within 60 day prior visit 1 ( day 1 ) ( use inhale , intranasal , topical corticosteroid allow ) ; 2 . Receipt parenteral steroid within 60 day prior visit 1 ( day 1 ) ; 3 . Receipt immunostimulants within 60 day prior visit 1 ( day 1 ) ; 4 . Receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivates within 3 month prior visit 1 ( day 1 ) plan full length study ; 5 . HIV infection HIVrelated disease ; 6 . Heritable immunodeficiency . 13 . Abnormalities splenic thymic function . 14 . Individuals know bleed diathesis , condition might associate prolonged bleeding time . 15 . Individuals serious chronic progressive disease accord judgment investigator ( neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . 16 . Individuals body mass index ( BMI ) great equal 35 kg/m2 ( = weight kg / ( height meter x height meter ) ) . 17 . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . 18 . Individuals receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment study plan receive vaccine Td placebo within 28 day study vaccine . 19 . Individuals first degree relative subject involve trial conduct . 20 . Individuals history substance alcohol abuse within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pertussis</keyword>
	<keyword>booster vaccine</keyword>
	<keyword>tetanus</keyword>
	<keyword>diphtheria adult</keyword>
</DOC>